Biotech company MannKind (MNKD 1.24%) reported its fourth-quarter results last week, and it looks like the debate over its long-term potential will continue until the company releases the trial results for its ultra-rapid insulin, Afrezza. In the company's latest conference call, however, there were questions related to future partnerships.
Could there be a collaboration on the horizon for this biotech, or should investors resist getting their hopes up for the time being? Health care analyst Max Macaluso discusses this topic in the following video.
